---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000036"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:40:30.748020+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus

## Summary
- Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.
- Cash, cash equivalents, and marketable securities $345.9M as of Mar 31, 2024, funding operations into Q1 2026.
- FDA IND clearance for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 trial expected to start by YE 2024.
- Plans to present initial CB-010 dose expansion data at ASCO June 3, 2024; initial CB-011 data by YE 2024.
- Licensing and collaboration revenue $2.4M, down from $3.5M due to terminated AbbVie agreement.

## SEC filing metadata
- accession: 0001619856-24-000036
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/0001619856-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/crbu-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000036
- JSON: https://secwatch.observer/filing/0001619856-24-000036.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000036.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $2.4 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $2.4 million
  - Result: reported results
  source text: Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $2.4 million for the three months ended March 31, 2024, compared to $3.5 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/0001619856-24-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.